June 26, 2026 at 10:16 AM 2 min readhealthAI Insights

Health Ministry Expands QR Code Authentication for Critical Medicines

[Expanded Authentication Framework]:

The Union Health Ministry has announced a significant expansion of its QR code-based drug authentication framework. Starting in July 2027, manufacturers will be mandated to incorporate barcodes or QR codes on packaging for vaccines, anti-cancer drugs, and psychiatric medications. This requirement will extend to antimicrobials, including antibiotics, by July 2028. This initiative builds upon the existing track-and-trace mechanism that previously covered only the top 300 pharmaceutical brands.

[Curbing Spurious Drugs]:

The primary objective of this policy is to strengthen product verification and effectively curb the circulation of spurious and substandard medicines within the Indian market. By digitizing the supply chain, the government aims to provide consumers and pharmacists with a reliable method to verify the authenticity of critical life-saving drugs. This move is expected to enhance patient safety and restore trust in the pharmaceutical distribution network.

[Supply Chain Efficiency]:

In a related effort to streamline pharmaceutical logistics, the Ministry has proposed amendments to the Drugs Rules, 1945. The draft notification suggests that imported drugs must have a minimum residual shelf life of 12 months at the time of import, replacing the current 60% requirement. While this change aims to reduce wastage and improve availability, biological products and radiopharmaceuticals will remain subject to the existing 60% rule due to their specialized nature. Public comments are currently being invited to refine these regulatory updates.
Pulse Intelligence
AI Analysis
  • The existing track-and-trace system was previously limited to the top 300 pharma brands.
  • The Union Health Ministry is amending the Drugs Rules, 1945.
  • Spurious drugs have been a long-standing concern for Indian public health authorities.
  • Pharmaceutical manufacturers will need to upgrade packaging infrastructure by 2027.
  • Patient safety is expected to improve through easier verification of life-saving drugs.
  • Imported drug availability may increase due to the revised shelf-life requirements.

Pharma companies may face increased compliance costs, but the move will likely boost long-term brand trust.